Kutatási jelek – Signal Engine

• 285 Glioblastoma Clinical Trials Recruiting Now (September 2026): GBM, MGMT, TTFields, GammaTile, CAR-T — Glioblastoma
• Colorectal Cancer: Diagnosis and Management | CancerNetwork — Colorectal cancer
• August Clinical Trial Roundup for Metastatic Colorectal Cancer — Colorectal cancer
• Statistical Robustness and Follow-up Completeness of Survival Outcomes in Phase III Breast Cancer Trials — Breast cancer
• Current FDA-Approved Medications — Multiple myeloma
• Nasopharyngeal Carcinoma Clinical Trials (September 2026): 164 Recruiting — Nasopharyngeal carcinoma
• Thyroid cancer: patients' experiences of receiving iodine‑131 therapy — Thyroid cancer
• Research articles | Leukemia — Acute lymphoblastic leukemia
• Nivolumab-Based Treatment Yields Long-Term Survival in Resectable NSCLC — NSCLC
• Pancreatic Cancer Drug Rasonque Shows Early Promise Against RAS‑Mutated Lung Cancer Too — NSCLC
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer - KONQUER‑101 Study — NSCLC
• Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study — Hodgkin lymphoma
• Trial Examining BEMPEG/ Nivolumab Combination Discontinues — Renal cell carcinoma
• Promising Early Activity With VERU-111 Provides Proof-of-Concept for Phase III Research in mCRPC — Prostate cancer
• Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden — Anal squamous cell carcinoma
• Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy — Renal cell carcinoma
• Browse Breast Cancer Clinical Trials - BreastCancerTrials.org — Breast cancer
• Oral targeted therapy slows pancreatic cancer growth, improves overall survival - ASCO — Pancreatic cancer
• Tumor Diameter of Melanoma Demonstrates Statistically Significant Correlation With Survival — Melanoma
• Small Cell Lung Cancer — SCLC